Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (unaudited)

v3.7.0.1
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Income Statement [Abstract]        
Contract research and government grants $ 294,464 $ 234,334 $ 453,532 $ 234,334
Revenue 14,500 14,500
Total revenue 308,964 234,334 468,032 234,334
Operating expenses        
Research and development 1,162,138 375,779 2,590,698 1,049,391
General and administrative expenses 1,203,641 480,757 4,533,652 1,966,561
Total operating expenses 2,365,779 856,536 7,124,350 3,015,952
Loss from operations (2,056,815) (622,202) (6,656,318) (2,781,618)
Other income (expense)        
Other income 500 500
Interest income 671 305 970 1,153
Change in fair value of derivative liabilities (8,028) (127,994) (877,490) (108,565)
Total other income (expense) (7,357) (127,189) (876,520) (106,912)
Net loss $ (2,064,172) $ (749,391) $ (7,532,838) $ (2,888,530)
Net loss per common share - basic and diluted (in dollars per share) $ (0.12) $ (0.06) $ (0.46) $ (0.22)
Weighted average common shares outstanding - basic and diluted (in shares) 17,691,114 13,161,247 16,419,225 12,854,810